PURPOSE: To compare modified Early Treatment @entity6 Study (mETDRS) focal/grid laser photocoagulation with normal-density (ND-SDM) or high-density ( @entity2033 -SDM) subthreshold diode-laser micropulse photocoagulation for the treatment @entity1103 ( @entity1103 ). METHODS: A prospective, randomized, controlled, double-masked clinical trial with @entity1 with previously untreated @entity1103 and best corrected visual acuity (BCVA) worse than 20/40 and better than 20/400. @entity1 were randomized to receive either mETDRS focal/grid photocoagulation (42 @entity1 ), ND-SDM (39 @entity1 ), or @entity2033 -SDM (42 @entity1 ). Before treatment and 1, 3, 6, and 12 months after treatment, all @entity1 underwent ophthalmic examinations, BCVA, color fundus photography, @entity941 angiography, and optical coherence tomography (OCT). RESULTS: At 12 months, the @entity2033 -SDM group had the best improvement in BCVA (0.25 logMAR), followed by the mETDRS group (0.08 logMAR), whereas no improvements were seen in the ND-SDM group (0.03 logMAR). All groups showed statistically significant progressive reduction of central macular thickness (CMT) throughout the study (P < 0.001). The @entity2033 -SDM group exhibited the greatest CMT reduction (154  m), which was not significantly different from that of the mETDRS group (126  m; P = 0.75). CONCLUSIONS: At 1 year, the clinical performance of @entity2033 -SDM was superior to that of the mETDRS photocoagulation technique, according to the anatomic and functional measures of improvement used in this investigation. A rationale for this treatment modality as a preferable approach is suggested, and the precise role of subthreshold micropulse laser treatment may become more defined as experience grows, guided by optimized treatment guidelines and more comprehensive trials. (Clinicaltrials.gov number, NCT00552435.).

Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['DME', 'diabetic macular edema'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']
@entity1103 :: (MESH:D008269,Disease) :: ['diabetic macular edema']
